Etravirine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C20H15BrN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C50HW4FO1, chemically known as benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl- but generally known as etravirine, which bears US NIH Compound Identifier 193962. European Medicines Agency schedules Etravirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25650. The term ETRAVIRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules etravirine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule etravirine under HS 29335995 and SITC 51576. As of Q4 2014, ETRAVIRINE remains the US FDA Preferred Term for this commodity. Etravirine bears US NLM identifiers UMLS ID C1456409 and NCI Concept Code C73195. SMILES: Brc1c(Oc2c(cc(cc2C)C#N)C)nc(Nc2ccc(cc2)C#N)nc1N.